Search results for "Immune system"

showing 10 items of 2885 documents

Proteome response of Tribolium castaneum larvae to Bacillus thuringiensis toxin producing strains.

2012

Susceptibility of Tribolium castaneum (Tc) larvae was determined against spore-crystal mixtures of five coleopteran specific and one lepidopteran specific Bacillus thuringiensis Cry toxin producing strains and those containing the structurally unrelated Cry3Ba and Cry23Aa/Cry37Aa proteins were found toxic (LC(50) values 13.53 and 6.30 µg spore-crystal mixture/µL flour disc, respectively). Using iTRAQ combined with LC-MS/MS allowed the discovery of seven novel differentially expressed proteins in early response of Tc larvae to the two active spore-crystal mixtures. Proteins showing a statistically significant change in treated larvae compared to non-intoxicated larvae fell into two major cat…

Models MolecularProteomicsProteomeTranscription GeneticOdorant bindingProtein ConformationApplied Microbiologylcsh:MedicinePathogenesismedicine.disease_causeReceptors OdorantBiochemistryProtein structureBacillus thuringiensislcsh:SciencePhylogenyTriboliumMultidisciplinaryImmune System ProteinsSpectrometric Identification of ProteinsbiologyChemosensory proteinAgricultureHost-Pathogen InteractionLarvaHost-Pathogen InteractionsInsect ProteinsResearch Articleanimal structuresProtein subunitLipoproteinsBacterial ToxinsMolecular Sequence DataBacillus thuringiensisMicrobiologyBacterial ProteinsRibosomal proteinMicrobial ControlDefense ProteinsmedicineAnimalsAmino Acid SequencePesticidesBiologyToxinfungilcsh:RProteinsbiology.organism_classificationMolecular biologyApolipoproteinsOdorant-binding proteinbiology.proteinlcsh:QPest ControlSequence AlignmentZoologyEntomologyProtein AbundancePLoS ONE
researchProduct

Pharmacy and pharmacology of biosimilars

2008

Biosimilar medicines are biological medicinal products that can obtain a marketing authorization in the EU after the original product (biological reference medicine) has run out of patent. As a prerequisite, studies including clinical trials are to be conducted to compare the quality, safety, and efficacy of the biosimilar and reference medicine. Due to the specific characteristics of biopharmaceuticals like complex 3-dimensional (glyco) protein structure, immunogenicity, production in living organisms, which causes heterogeneity, complex manufacturing process and analysis, interchangeability of the biosimilar with its reference drug product is not guaranteed. In addition, INN (internationa…

Models MolecularQuality ControlDrug IndustryTraceabilityEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectPharmacyPharmacyPharmacologyMarketing authorizationInterchangeabilityEndocrinologyPharmacovigilanceHumansMedicineQuality (business)media_commonPharmacologybusiness.industryBiosimilarProduct (business)Pharmaceutical PreparationsTherapeutic EquivalencyImmune SystembusinessAlgorithmsJournal of Endocrinological Investigation
researchProduct

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.

2002

Virus like particles (VLPs) are known to induce potent B cell responses in the absence of adjuvants. Moreover, epitope-specific antibody responses may be induced by VLPs that contain peptides inserted in their immunodominant regions. However, due to steric problems, the size of the peptides capable of being incorporated into VLPs while still permitting capsid assembly, is rather limited. While peptides genetically fused to either the N- or C-terminus of VLPs present fewer assembly problems, the immune responses obtained against such epitopes are often limited, most likely because the epitopes are not optimally exposed. In addition, such particles may be less stable in vivo. Here, we show th…

Models MolecularViral Hepatitis VaccinesHepatitis B virusMacromolecular SubstancesProtein ConformationvirusesRecombinant Fusion ProteinsProtozoan ProteinsAntigens ProtozoanBiologyProtein EngineeringEpitopePhospholipases AInclusion Bodies ViralViral Matrix ProteinsMiceImmune systemAntigenVirus-like particlemedicineAnimalsB cellB-LymphocytesMice Inbred BALB CVaccines SyntheticGeneral VeterinaryGeneral Immunology and MicrobiologyImmunodominant EpitopesImmunogenicityVaccinationPublic Health Environmental and Occupational HealthMolecular biologyHepatitis B Core AntigensPeptide FragmentsCell biologyProtein Structure TertiaryHBcAgBee VenomsInfectious Diseasesmedicine.anatomical_structureCross-Linking ReagentsCapsidDrug DesignMolecular MedicineFemaleImmunizationPeptidesOligopeptidesVaccine
researchProduct

Pharmacology and safety of tofacitinib in ulcerative colitis.

2020

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC). It is a small synthetic molecule administered orally, with a fast bioavailability and elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of tofacitinib and its safety profile.

Moderate to severePharmacologyHerpes ZosterArthritis Rheumatoid03 medical and health sciences0302 clinical medicineImmune systemPharmacokineticsPiperidinesNeoplasmsMedicineHerpes Zoster VaccineHumansJanus Kinase InhibitorsDrug InteractionsTofacitinibbusiness.industryImmunogenicityJanus Kinase 3Janus Kinase 1Venous Thromboembolismmedicine.diseaseUlcerative colitisBioavailabilityPyrimidines030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeJanus kinasebusinessGastroenterologia y hepatologia
researchProduct

Identification and relevance of the CD95-binding domain in the N-terminal region of ezrin.

2003

The CD95 (Fas/APO-1) linkage to the actin cytoskeleton through ezrin is an essential requirement for susceptibility to the CD95-mediated apoptosis in CD4+ T cells. We have previously shown that moesin was not involved in the binding to CD95. Here we further support the specificity of the ezrin/CD95 binding, showing that radixin did not bind CD95. The ezrin region specifically and directly involved in the binding to CD95 was located in the middle lobe of the ezrin FERM domain, between amino acids 149 and 168. In this region, ezrin, radixin, and moesin show 60-65% identity, as compared with the 86% identity in the whole FERM domain. Transfection of two different human cell lines with a green …

Moesinchemical and pharmacologic phenomenaApoptosismacromolecular substancesBiologyBiochemistryEzrinRadixinhemic and lymphatic diseasesHumansfas ReceptorMolecular BiologyActinBinding SitesFERM domainhemic and immune systemsCell BiologyTransfectionActin cytoskeletonPhosphoproteinsActinsCell biologyProtein Structure TertiaryCytoskeletal ProteinsMutationbiological phenomena cell phenomena and immunityBinding domainHeLa CellsProtein BindingSignal TransductionThe Journal of biological chemistry
researchProduct

Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor…

2011

A shot in the arm for cancer treatment: two MUC1 tetanus toxoid vaccines were synthesized and induced a strong immune response in mice. The antibodies elicited by the vaccines show a high selectivity for the tumor cells in mammary carcinoma tissues and also distinguish between tumor tissues at different stages.

Molecular ConformationAntineoplastic AgentsBreast Neoplasmscomplex mixturesCancer VaccinesCatalysisBreast tumorMiceImmune systemmedicineAnimalsMUC1Mice Inbred BALB CVaccines SyntheticbiologyTetanusChemistryMucin-1ToxoidGlycopeptidesMammary Neoplasms ExperimentalGeneral Chemistrymedicine.diseaseGlycopeptideCancer researchbiology.proteinMCF-7 CellsExperimental pathologyFemaleAntibodyDrug Screening Assays AntitumorAngewandte Chemie (International ed. in English)
researchProduct

A bicistronic vector backbone for rapid seamless cloning and chimerization of αβT-cell receptor sequences.

2020

To facilitate preclinical testing of T-cell receptors (TCRs) derived from tumor-reactive T-cell clones it is necessary to develop convenient and rapid cloning strategies for the generation of TCR expression constructs. Herein, we describe a pDONR™221 vector backbone allowing to generate Gateway™ compatible entry clones encoding optimized bicistronic αβTCR constructs. It harbors P2A-linked TCR constant regions and head-to-head-oriented recognition sites of the Type IIS restriction enzymes BsmBI and BsaI for seamless cloning of the TCRα and TCRβ V(D)J regions, respectively. Additional well-established TCR optimizations were incorporated to enhance TCR functionality. This included replacing of…

Molecular biologyReceptors Antigen T-Cell alpha-betaT-LymphocytesArtificial Gene Amplification and ExtensionPolymerase Chain ReactionImmune ReceptorsBiochemistryWhite Blood CellsTransduction (genetics)Animal CellsTransduction GeneticCellular typesChlorocebus aethiopsMedicine and Health SciencesCytotoxic T cellCloning MolecularImmune System ProteinsMultidisciplinaryCOS cellsChemistryV(D)J recombinationQRVector Constructionmedicine.anatomical_structureCOS CellsMedicineResearch ArticleSignal TransductionCell biologyBlood cellsImmune CellsT cellScienceImmunologyGenetic VectorsT cellsCytotoxic T cellsComputational biologyDNA constructionResearch and Analysis MethodsCell LineGene Expression and Vector TechniquesmedicineAnimalsHumansMolecular Biology TechniquesCloningMolecular Biology Assays and Analysis TechniquesBiology and life sciencesT-cell receptorProteinsVector CloningCoculture TechniquesV(D)J RecombinationT Cell ReceptorsRestriction enzymeHEK293 CellsRetroviridaePlasmid ConstructionCloningPLoS ONE
researchProduct

The triad hsp60-mirnas-extracellular vesicles in brain tumors: Assessing its components for understanding tumorigenesis and monitoring patients

2021

Brain tumors have a poor prognosis and progress must be made for developing efficacious treatments, but for this to occur their biology and interaction with the host must be elucidated beyond current knowledge. What has been learned from other tumors may be applied to study brain tumors, for example, the role of Hsp60, miRNAs, and extracellular vesicles (EVs) in the mechanisms of cell proliferation and dissemination, and resistance to immune attack and anticancer drugs. It has been established that Hsp60 increases in cancer cells, in which it occurs not only in the mitochondria but also in the cytosol and plasma-cell membrane and it is released in EVs into the extracellular space and in cir…

Molecular chaperonesCellBrain tumorBiologymedicine.disease_causelcsh:Technologylcsh:Chemistry03 medical and health sciences0302 clinical medicineImmune systemHigh-grade gliomaExtracellularmedicineGeneral Materials Sciencelcsh:QH301-705.5Instrumentation030304 developmental biologyFluid Flow and Transfer Processes0303 health sciencesLiquid biopsylcsh:TProcess Chemistry and TechnologyGeneral EngineeringCancerTumor biomarkersChaperonopathiesExtracellular vesiclesmedicine.diseaseHsp60lcsh:QC1-999Computer Science ApplicationsCrosstalk (biology)medicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040030220 oncology & carcinogenesisCancer cellCancer researchChaperone systemMiRNAslcsh:Engineering (General). Civil engineering (General)CarcinogenesisGlioblastomaMeningiomalcsh:Physics
researchProduct

2015

Regulatory T cells (Treg) control immune cell function as well as non-immunological processes. Their far-reaching regulatory activities suggest their functional manipulation as a means to sustainably and causally intervene with the course of diseases. Preclinical tools and strategies are however needed to further test and develop interventional strategies outside the human body. "Humanized" mouse models consisting of mice engrafted with human immune cells and tissues provide new tools to analyze human Treg ontogeny, immunobiology, and therapy. Here, we summarize the current state of humanized mouse models as a means to study human Treg function at the molecular level and to design strategie…

Molecular levelImmune systembusiness.industryImmunologyHumanized mouseImmunologyImmunology and AllergyImmune Cell FunctionMedicinebusinessFrontiers in Immunology
researchProduct

Zinc oxide nanorod based immunosensing platform for the determination of human leukemic cells.

2019

Zinc oxide (ZnO) based nanostructures owing unique physical properties – high photoluminescence, bio- compatibility and other characteristics, therefore, they attract attention as building blocks suitable for biosensor development. In this research as a target we have used human leukemic cell line IM9 (IM9). IM9 was derived from the patient with a multiple myeloma and expressed cluster of differentiation proteins СD19 on the surface of 85–95% here investigated cancer cells. As a control sample healthy human's peripheral blood mononuclear cells (PBMC) were used and the expression of CD19 protein was found only in 5–9% of these cells. Two types of antibodies labeled by f…

Monoclonal antibodymedicine.drug_class02 engineering and technologyCell SeparationMonoclonal antibody01 natural sciencesCD19Analytical ChemistryFlow cytometrychemistry.chemical_compoundHuman lymphocytesmedicineHumansFlow cytometryZnO-nanorodsFluorescein isothiocyanatePhotoluminescenceCells CulturedImmunoassayB-LymphocytesLeukemiaNanotubesCluster of differentiationmedicine.diagnostic_testbiology010401 analytical chemistryhemic and immune systemsВ-lymphoblast cells021001 nanoscience & nanotechnologyFlow CytometryMolecular biologyhumanities0104 chemical scienceschemistryCell cultureCancer cell:NATURAL SCIENCES [Research Subject Categories]biology.proteinAntibodyZinc Oxide0210 nano-technologyhuman activitiesBiomarkersTalanta
researchProduct